Gil M. Labrucherie Buys 6,282 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie acquired 6,282 shares of Septerna stock in a transaction on Tuesday, February 25th. The shares were bought at an average price of $5.59 per share, for a total transaction of $35,116.38. Following the completion of the purchase, the chief financial officer now directly owns 36,282 shares in the company, valued at $202,816.38. The trade was a 20.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Septerna Stock Performance

Shares of NASDAQ:SEPN opened at $6.47 on Friday. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The business’s fifty day simple moving average is $16.08.

Wall Street Analysts Forecast Growth

SEPN has been the topic of a number of research analyst reports. TD Cowen initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a “buy” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company cut shares of Septerna from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $43.00 to $14.00 in a report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC acquired a new stake in shares of Septerna in the 4th quarter worth about $25,419,000. TRV GP V LLC bought a new position in Septerna in the 4th quarter worth about $142,337,000. TRV GP VI LLC acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $72,191,000. Vanguard Group Inc. bought a new stake in shares of Septerna during the fourth quarter valued at approximately $22,557,000. Finally, Corebridge Financial Inc. bought a new stake in shares of Septerna during the fourth quarter valued at approximately $212,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.